Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 26, 2026
Provectus Biopharmaceuticals, Inc. (PVCT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $1.2 million in cash and investments and $103,900 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-982,566
+45.8% vs year-ago quarter
Operating cash flow
$-358,249
+31.5% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
420.28M
+0.0% vs year-ago quarter
Net cash
$1.05M
Q2 FY2026
Operating margin
-379.5%
Q3 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PVCT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Knoxville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 315545
- Former names
- PROVECTUS PHARMACEUTICALS INC (until Dec 18, 2013); PROVECTUS PHARMACEUTICAL INC (until May 15, 2002); ZAMAGE DIGITAL IMAGING INC (until Apr 1, 2002); SPM GROUP INC (until Nov 14, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $336,108 | $57,480 |
| Operating income | -$938,678 | -$1.2M | -$1.1M | -$1.3M | -$1.8M |
| Net income | -$982,566 | -$1.3M | -$1.2M | -$1.3M | -$1.8M |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$358,249 | -$357,565 | -$869,553 | -$839,867 | -$523,127 |
| Total assets | $1.5M | $577,580 | $697,502 | $419,904 | $722,384 |
| Total liabilities | $7.8M | $7.3M | $7.0M | $6.6M | $6.6M |
| Stockholders' equity | -$6.3M | -$6.7M | -$6.3M | -$6.2M | -$5.9M |
| Cash and investments | $1.2M | $223,883 | $251,291 | $72,479 | $385,929 |
| Total debt | $103,900 | $115,674 | $127,304 | $138,789 | $150,132 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 1000 Provectus Biopharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.